Search

Your search keyword '"Aragri A."' showing total 141 results
Start Over Author "Aragri A." Publication Type Academic Journals
141 results on '"Aragri A."'

1. Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

Author

Luca Foroghi Biland, Ludovica Ferrari, Vincenzo Malagnino, Elisabetta Teti, Carlotta Cerva, Adele Gentile, Marianna Aragri, Romina Salpini, Valentina Svicher, Massimo Andreoni, and Loredana Sarmati

Subjects
Hepatitis B virus, HBV reactivation, Direct acting antivirals, Coinfection HBV/HCV, Immune-escape HBV mutant, Medicine
Abstract

Abstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. Case presentation We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region. Conclusions We speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.

Published
2019
Full Text
View/download PDF

3. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B

Author

Aragri, Marianna, Alteri, Claudia, Battisti, Arianna, Di Carlo, Domenico, Minichini, Carmine, Sagnelli, Caterina, Bellocchi, Maria Concetta, Pisaturo, Maria Antonietta, Starace, Mario, Armenia, Daniele, Carioti, Luca, Pollicita, Michela, Salpini, Romina, Sagnelli, Evangelista, Perno, Carlo Federico, Coppola, Nicola, and Svicher, Valentina

Published
2016

4. Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

Author

Foroghi Biland, Luca, Ferrari, Ludovica, Malagnino, Vincenzo, Teti, Elisabetta, Cerva, Carlotta, Gentile, Adele, Aragri, Marianna, Salpini, Romina, Svicher, Valentina, Andreoni, Massimo, and Sarmati, Loredana

Published
2019
Full Text
View/download PDF

5. Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district

Author

Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio VC, Sciacca A, Santoleri F, Fazii P, Costantini A, Perno CF, and Parruti G

Subjects
HCV, HCV sequence analysis, HCV genotype, Direct Acting Antiviral, Treatment costs, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Ennio Polilli,1 Valeria Cento,2 Umberto Restelli,3,4 Francesca Ceccherini-Silberstein,2 Marianna Aragri,2 Velia Chiara Di Maio,2 Antonina Sciacca,1 Fiorenzo Santoleri,5 Paolo Fazii,6 Alberto Costantini,5 Carlo Federico Perno,2 Giustino Parruti1 1Infectious Diseases Unit, Pescara General Hospital, Pescara, 2Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, 3CREMS - Centre for Research on Health Economics, Social and Health Care Management, Carlo Cattaneo – LIUC University, Castellanza, Italy; 4School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 5Hospital Pharmacy, Pescara General Hospital, 6Microbiology and Virology Unit, Pescara General Hospital, Pescara, Italy Abstract: Available commercial assays may yield inaccurate hepatitis C virus (HCV) genotype assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) regimen. Between March and September 2015, HCV sequence analysis was performed in order to confirm commercial LiPA-HCV genotype (Versant® HCV Genotype 2.0) in patients eligible for treatment with DAAs. Out of 134 consecutive patients enrolled, sequencing yielded 21 (15.7%) cases of discordant results. For three cases of wrong genotype assignment, the putative reduction in efficacy was gauged between 15% and 40%. Among the eight cases for whom G1b was assigned by commercial assays instead of G1a, potentially suboptimal treatments would have been prescribed. Finally, for five patients with G1 and indeterminate subtype, the choice of regimens would have targeted the worst option, with a remarkable increase in costs, as in the case of the four mixed HCV infections for whom pan-genotypic regimens would have been mandatory. Precise assignment of HCV genotype and subtype by sequencing may, therefore, be more beneficial than expected, until more potent pan-genotypic regimens are available for all patients. Keywords: HCV, HCV sequence analysis, HCV genotype, direct acting antiviral, treatment costs

Published
2016

6. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

Author

Cento, Valeria, Di Paolo, Daniele, Di Carlo, Domenico, Micheli, Valeria, Tontodonati, Monica, De Leonardis, Francesco, Aragri, Marianna, Antonucci, Francesco Paolo, Di Maio, Velia Chiara, Mancon, Alessandro, Lenci, Ilaria, Manunta, Alessandra, Taliani, Gloria, Di Biagio, Antonio, Nicolini, Laura Ambra, Nosotti, Lorenzo, Sarrecchia, Cesare, Siciliano, Massimo, Landonio, Simona, Pellicelli, Adriano, Gasbarrini, Adriano, Vecchiet, Jacopo, Magni, Carlo Federico, Babudieri, Sergio, Mura, Maria Stella, Andreoni, Massimo, Parruti, Giustino, Rizzardini, Giuliano, Angelico, Mario, Perno, Carlo Federico, and Ceccherini-Silberstein, Francesca

Published
2015
Full Text
View/download PDF

7. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro

Author

Romina Salpini, Lorenzo Piermatteo, Arianna Battisti, Luna Colagrossi, Marianna Aragri, Katia Yu La Rosa, Ada Bertoli, Patrizia Saccomandi, Miriam Lichtner, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Nerio Iapadre, Carlotta Cerva, Stefano Aquaro, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Jens Verheyen, Francesca Ceccherini-Silberstein, Massimo Levrero, Carlo Federico Perno, Laura Belloni, and Valentina Svicher

Subjects
hbv, hbv reactivation, hbsag, n-linked glycosylation, Microbiology, QR1-502
Abstract

Immune-suppression driven Hepatitis B Virus (HBV)-reactivation poses serious concerns since it occurs in several clinical settings and can result in severe forms of hepatitis. Previous studies showed that HBV strains, circulating in patients with HBV-reactivation, are characterized by an enrichment of immune-escape mutations in HBV surface antigen (HBsAg). Here, we focused on specific immune-escape mutations associated with the acquisition of N-linked glycosylation sites in HBsAg (NLGSs). In particular, we investigated profiles of NLGSs in 47 patients with immunosuppression-driven HBV-reactivation and we evaluated their impact on HBsAg-antigenicity and HBV-replication in vitro. At HBV-reactivation, despite a median serum HBV-DNA of 6.7 [5.3−8.0] logIU/mL, 23.4% of patients remained HBsAg-negative. HBsAg-negativity at HBV-reactivation correlated with the presence of >1 additional NLGSs (p < 0.001). These NLGSs are located in the major hydrophilic region of HBsAg (known to be the target of antibodies) and resulted from the single mutation T115N, T117N, T123N, N114ins, and from the triple mutant S113N+T131N+M133T. In vitro, NLGSs strongly alter HBsAg antigenic properties and recognition by antibodies used in assays for HBsAg-quantification without affecting HBsAg-secretion and other parameters of HBV-replication. In conclusion, additional NLGSs correlate with HBsAg-negativity despite HBV-reactivation, and hamper HBsAg-antigenicity in vitro, supporting the role of NGSs in immune-escape and the importance of HBV-DNA for a proper diagnosis of HBV-reactivation.

Published
2020
Full Text
View/download PDF

8. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy

Author

Bertoli, Ada, Sorbo, Maria Chiara, Aragri, Marianna, Lenci, Ilaria, Teti, Elisabetta, Polilli, Ennio, Di Maio, Velia Chiara, Gianserra, Laura, Biliotti, Elisa, Masetti, Chiara, Magni, Carlo F., Babudieri, Sergio, Nicolini, Laura A., Milana, Martina, Cacciatore, Pierluigi, Sarmati, Loredana, Pellicelli, Adriano, Paolucci, Stefania, Craxì, Antonio, Morisco, Filomena, Palitti, Valeria Pace, Siciliano, Massimo, Coppola, Nicola, Iapadre, Nerio, Puoti, Massimo, Rizzardini, Giuliano, Taliani, Gloria, Pasquazzi, Caterina, Andreoni, Massimo, Parruti, Giustino, Angelico, Mario, Perno, Carlo Federico, Cento, Valeria, Ceccherini-Silberstein, Francesca, and HCV Virology Italian Resistance Network (VIRONET-C)

Published
2018
Full Text
View/download PDF

10. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients

Author

Maria Concetta Bellocchi, Marianna Aragri, Luca Carioti, Lavinia Fabeni, Rosaria Maria Pipitone, Giuseppina Brancaccio, Maria Chiara Sorbo, Silvia Barbaliscia, Velia Chiara Di Maio, Fabrizio Bronte, Stefania Grimaudo, Walter Mazzucco, Ferdinando Frigeri, Marco Cantone, Antonio Pinto, Carlo Federico Perno, Antonio Craxì, Giovanni Battista Gaeta, Vito Di Marco, and Francesca Ceccherini-Silberstein

Subjects
HCV, acute infection, chronic infection, nosocomial transmission, sequencing, NGS, Cytology, QH573-671
Abstract

Background: The aim of the study was to investigate the intra-host variability through next-generation-sequencing (NGS) of the NS5A-gene in nosocomial transmission-clusters observed in two Italian hospitals among hepatitis C virus (HCV)-genotype-1b infected patients. Methods: HCV-sequencing was performed by Sanger-sequencing (NS3 + NS5A + NS5B) and by NGS (NS5A, MiSeq-Illumina) in 15 HCV-1b infected patients [five acute with onco-hematologic-disease and 10 (4/6 acute/chronic) with β-thalassemia]. Resistance-associated-substitutions (RAS) were analysed by Geno2pheno-algorithm. Nucleotide-sequence-variability (NSV, at 1%, 2%, 5%, 10% and 15% NGS-cutoffs) and Shannon entropy were estimated. Phylogenetic analysis was performed by Mega6-software and Bayesian-analysis. Results: Phylogenetic analysis showed five transmission-clusters: one involving four HCV-acute onco-hematologic-patients; one involving three HCV-chronic β-thalassemia-patients and three involving both HCV-acute and chronic β-thalassemia-patients. The NS5A-RAS Y93H was found in seven patients, distributed differently among chronic/acute patients involved in the same transmission-clusters, independently from the host-genetic IL-28-polymorphism. The intra-host NSV was higher in chronic-patients versus acute-patients, at all cutoffs analyzed (p < 0.05). Even though Shannon-entropy was higher in chronic-patients, significantly higher values were observed only in chronic β-thalassemia-patients versus acute β-thalassemia-patients (p = 0.01). Conclusions: In nosocomial HCV transmission-clusters, the intra-host HCV quasispecies divergence in patients with acute-infection was very low in comparison to that in chronic-infection. The NS5A-RAS Y93H was often transmitted and distributed differently within the same transmission-clusters, independently from the IL-28-polymorphism.

Published
2019
Full Text
View/download PDF

11. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

Author

Di Maio, V. C., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., Micheli, V., Bellocchi, M. C., Antonucci, F. P., Bertoli, A., Lenci, I., Milana, M., Gianserra, L., Melis, M., Di Biagio, A., Sarrecchia, C., Sarmati, L., Landonio, S., Francioso, S., Lambiase, L., Nicolini, L. A., Marenco, S., Nosotti, L., Giannelli, V., Siciliano, M., Romagnoli, D., Pellicelli, A., Vecchiet, J., Magni, C. F., Babudieri, S., Mura, M. S., Taliani, G., Mastroianni, C., Vespasiani-Gentilucci, U., Romano, M., Morisco, F., Gasbarrini, A., Vullo, V., Bruno, S., Baiguera, C., Pasquazzi, C., Tisone, G., Picciotto, A., Andreoni, M., Parruti, G., Rizzardini, G., Angelico, M., Perno, C. F., Ceccherini-Silberstein, F., Mariani, R., Paoloni, M., Iapadre, N., Grimaldi, A., Menzaghi, B., Quirino, T., Vecchiet, J., Bruzzone, B., De Maria, A., Di Biagio, A., Marenco, S., Nicolini, L. A., Picciotto, A., Viscoli, C., Casinelli, K., Monache, M. Delle, Lichtner, M., Mastroianni, C., Aghemo, A., Bruno, S., Cerrone, M., Colombo, M., Monforte, A. DʼArminio, Danieli, E., Donato, F., Gubertini, G., Landonio, S., Magni, C. F., Mancon, A., Micheli, V., Monico, S., Niero, F., Puoti, M., Rizzardini, G., Russo, M. L., Alfieri, R., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Romagnoli, D., Brancaccio, G., Caporaso, N., Gaeta, G. B., Lembo, V., Morisco, F., Calvaruso, V., Craxì, A., Di Marco, V., Mazzola, A., Petta, S., DʼAmico, E., Cacciatore, P., Consorte, A., Palitti, V. Pace, Parruti, G., Pieri, A., Polilli, E., Tontodonati, M., Andreoni, M., Angelico, M., Antenucci, F., Antonucci, F. P., Aragri, M., Armenia, D., Baiocchi, L., Bellocchi, M., Bertoli, A., Biliotti, E., Biolato, M., Carioti, L., Ceccherini-Silberstein, F., Cento, V., Cerasari, G., Cerva, C., Ciotti, M., DʼAmbrosio, C., DʼEttorre, G., De Leonardis, F., De Sanctis, A., Di Maio, V. C., Di Paolo, D., Francioso, S., Furlan, C., Gallo, P., Gasbarrini, A., Giannelli, V., Gianserra, L., Grieco, A., Grieco, S., Lambiase, L., Lattanzi, B., Lenci, I., Malagnino, V., Manuelli, M., Merli, M., Miglioresi, L., Milana, M., Nosotti, L., Palazzo, D., Pasquazzi, C., Pellicelli, A., Perno, C. F., Romano, M., Santopaolo, F., Santoro, M. M., Sarmati, L., Sarrecchia, C., Sforza, D., Siciliano, M., Sorbo, M. C., Spaziante, M., Svicher, V., Taliani, G., Teti, E., Tisone, G., Vespasiani-Gentilucci, U., Vullo, V., Mangia, A., Babudieri, S., Maida, I., Melis, M., Mura, M. S., Falconi, L., Di Giammartino, D., and Tarquini, P.

Published
2016
Full Text
View/download PDF

13. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Author

Salpini, Romina, Colagrossi, Luna, Bellocchi, Maria Concetta, Surdo, Matteo, Becker, Christina, Alteri, Claudia, Aragri, Marianna, Ricciardi, Alessandra, Armenia, Daniele, Pollicita, Michela, Di Santo, Fabiola, Carioti, Luca, Louzoun, Yoram, Mastroianni, Claudio Maria, Lichtner, Miriam, Paoloni, Maurizio, Esposito, Mariarosaria, DʼAmore, Chiara, Marrone, Aldo, Marignani, Massimo, Sarrecchia, Cesare, Sarmati, Loredana, Andreoni, Massimo, Angelico, Mario, Verheyen, Jens, Perno, Carlo-Federico, and Svicher, Valentina

Published
2015
Full Text
View/download PDF

18. Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy.

Author

Mazzucco, W., Chiara di Maio, V., Bronte, F., Fabeni, L., Pipitone, R.M., Grimaudo, S., Ferraro, D., Marotta, C., Aragri, M., Macaluso, M., Vitale, F., Di Raimondo, F., Ceccherini-Silberstein, F., Di Marco, V., Mazzucco, Walter, Chiara di Maio, Velia, Bronte, Fabrizio, Fabeni, Lavinia, Pipitone, Rosaria Maria, and Grimaudo, Stefania

Abstract

Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings.Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital.Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each gene employing Bayesian methods.Findings: All patients with acute hepatitis were infected with HCV genotype 1b. Root-cause analysis, including a lookback procedure, excluded blood donors as the source of HCV transmission. The phylogenetic analysis, conducted on seven patients with acute infection and eight patients with chronic infection, highlighted four transmission clusters including at least one patient with chronic and one patient with acute HCV infection. All patients in the same cluster received a blood transfusion during the same day. Two patients with acute hepatitis spontaneously cleared HCV within four weeks and nine patients received ledipasvir plus sofosbuvir for six weeks, all achieving a sustained virological response.Conclusion: Combined use of root-cause analysis and molecular epidemiology was effective in ascertaining the origin of the HCV outbreak. Antiviral therapy avoided the chronic progression of the infection and further spread in care units and in the family environment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. The role of a pre-load beverage on gastric volume and food intake: comparison between non-caloric carbonated and non-carbonated beverage

Author

Zito Francesco, Vozzella Letizia, Cirillo Carla, Aragri Adriana, Nicolai Emanuele, Sarnelli Giovanni, Savarese Maria, Cuomo Rosario, Verlezza Viviana, Efficie Eleonora, and Buyckx Maxime

Subjects
Carbonated beverage, gastric volume, calorie intake, liquid meal, solid meal, ghrelin, cholecystokinin, Nutrition. Foods and food supply, TX341-641, Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background There is conflicting data on the effects of carbon dioxide contained in beverages on stomach functions. We aimed to verify the effect of a pre-meal administration of a 300 ml non-caloric carbonated beverage (B+CO2) compared to water or a beverage without CO2 (B-CO2), during a solid (SM) and a liquid meal (LM) on: a) gastric volume, b) caloric intake, c) ghrelin and cholecystokinin (CCK) release in healthy subjects. Methods After drinking the beverages (Water, B-CO2, B+CO2), ten healthy subjects (4 women, aged 22-30 years; BMI 23 ± 1) were asked to consume either an SM or an LM, at a constant rate (110 kcal/5 min). Total gastric volumes (TGV) were evaluated by Magnetic Resonance Imaging after drinking the beverage and at maximum satiety (MS). Total kcal intake at MS was evaluated. Ghrelin and CCK were measured by enzyme immunoassay until 120 min after the meal. Statistical calculations were carried out by paired T-test and analysis of variance (ANOVA). The data is expressed as mean ± SEM. Results TGV after B+CO2 consumption was significantly higher than after B-CO2 or water (p < 0.05), but at MS, it was no different either during the SM or the LM. Total kcal intake did not differ at MS after any of the beverages tested, with either the SM (Water: 783 ± 77 kcals; B-CO2: 837 ± 66; B+CO2: 774 ± 66) or the LM (630 ± 111; 585 ± 88; 588 ± 95). Area under curve of ghrelin was significantly (p < 0.05) lower (13.8 ± 3.3 ng/ml/min) during SM following B-CO2 compared to B+CO2 and water (26.2 ± 4.5; 27.1 ± 5.1). No significant differences were found for ghrelin during LM, and for CCK during both SM and LM after all beverages. Conclusions The increase in gastric volume following a 300 ml pre-meal carbonated beverage did not affect food intake whether a solid or liquid meal was given. The consistency of the meal and the carbonated beverage seemed to influence ghrelin release, but were unable, under our experimental conditions, to modify food intake in terms of quantity. Further studies are needed to verify if other food and beverage combinations are able to modify satiation.

Published
2011
Full Text
View/download PDF

20. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.

Author

de Salazar, Adolfo, Dietz, Julia, di Maio, Velia Chiara, Vermehren, Johannes, Paolucci, Stefania, Müllhaupt, Beat, Coppola, Nicola, Cabezas, Joaquín, Stauber, Rudolf E, Puoti, Massimo, Arenas Ruiz Tapiador, Juan Ignacio, Graf, Christiana, Aragri, Marianna, Jimenez, Miguel, Callegaro, Annapaola, Pascasio Acevedo, Juan Manuel, Macias Rodriguez, Manuel Alberto, Rosales Zabal, Jose Miguel, Micheli, Valeria, and Garcia Del Toro, Miguel

Subjects
PROTEINS, AMINOBUTYRIC acid, RESEARCH, HETEROCYCLIC compounds, RESEARCH methodology, HEPATITIS viruses, ANTIVIRAL agents, RETROSPECTIVE studies, MEDICAL cooperation, EVALUATION research, HYDROCARBONS, COMPARATIVE studies, DISEASE prevalence, PROLINE, LEUCINE, GENOTYPES, REOPERATION, DRUG resistance in microorganisms, AMIDES, SULFONAMIDES, PHARMACODYNAMICS
Abstract

Objectives: To investigate resistance-associated substitutions (RASs) as well as retreatment efficacies in a large cohort of European patients with failure of glecaprevir/pibrentasvir.Methods: Patients were identified from three European Resistance Reference centres in Spain, Italy and Germany. Sequencing of NS3, NS5A and NS5B was conducted and substitutions associated with resistance to direct antiviral agents were analysed. Clinical and virological parameters were documented retrospectively and retreatment efficacies were evaluated.Results: We evaluated 90 glecaprevir/pibrentasvir failures [3a (n = 36), 1a (n = 23), 2a/2c (n = 20), 1b (n = 10) and 4d (n = 1)]. Ten patients were cirrhotic, two had previous exposure to PEG-interferon and seven were coinfected with HIV; 80 had been treated for 8 weeks. Overall, 31 patients (34.4%) failed glecaprevir/pibrentasvir without any NS3 or NS5A RASs, 62.4% (53/85) showed RASs in NS5A, 15.6% (13/83) in NS3 and 10% (9/90) in both NS5A and NS3. Infection with HCV genotypes 1a and 3a was associated with a higher prevalence of NS5A RASs. Patients harbouring two (n = 34) or more (n = 8) RASs in NS5A were frequent. Retreatment was initiated in 56 patients, almost all (n = 52) with sofosbuvir/velpatasvir/voxilaprevir. The overall sustained virological response rate was 97.8% in patients with end-of-follow-up data available.Conclusions: One-third of patients failed glecaprevir/pibrentasvir without resistance. RASs in NS5A were more prevalent than in NS3 and were frequently observed as dual and triple combination patterns, with a high impact on NS5A inhibitor activity, particularly in genotypes 1a and 3a. Retreatment of glecaprevir/pibrentasvir failures with sofosbuvir/velpatasvir/voxilaprevir achieved viral suppression across all genotypes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation.

Author

Salpini, Romina, Pietrobattista, Andrea, Piermatteo, Lorenzo, Basso, Maria Sole, Bellocchi, Maria C, Liccardo, Daniela, Carioti, Luca, Francalanci, Paola, Aragri, Marianna, Alkhatib, Mohammed, Scutari, Rossana, Candusso, Manila, Ciotti, Marco, Svicher, Valentina, Salpini, R, Pietrobattista, A, Piermatteo, L, Basso, M S, Bellocchi, M C, and Liccardo, D

Subjects
LIVER transplantation, RESERVOIRS, VACCINES, INFANTS, NUCLEOTIDE sequencing
Abstract

We describe the establishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a successfully vaccinated infant who underwent liver transplantation from an donor positive for antibody to hepatitis B core antigen (anti-HBc). The use of highly sensitive droplet digital polymerase chain reaction assays revealed a not negligible and transcriptionally active intrahepatic HBV reservoir (circular covalently closed DNA, relaxed circular DNA, and pregenomic RNA: 5.6, 2.4, and 1.1 copies/1000 cells, respectively), capable to sustain ongoing viral production and initial liver damage. Next-generation sequencing revealed a peculiar enrichment of hepatitis B surface antigen vaccine-escape mutations that could have played a crucial role in OBI transmission. This clinical case highlights the pathobiological complexity and the diagnostic challenges underlying OBI. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

22. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

Author

Barbaliscia, S., Di Maio, V.C., Fabeni, L., Teti, E., Paolucci, S., Minichini, C., Aragri, M., Rosa, K. Yu La, Carioti, L., Pasquazzi, C., Milana, M., Foroghi, L., Pollicino, T., Licata, A., Pieri, A., Palitti, V. Pace, Bruzzone, B., Micheli, V., Bertoli, A., Baiocchi, L., Callegaro, A.P., Pellicelli, A., Morisco, F., Gulminetti, R., Novati, S., Lichtner, M., Mastroianni, C., Di Lorenzo, F., Andreone, P., Rossetti, B., Marenco, S., Taliani, G., Boeri, E., Hasson, H., Monno, L., Nicolini, L.A., Landonio, S., Paternoster, C., Puoti, M., Babudieri, S., Quartini, M., Iapadre, N., Cozzolongo, R., Sangiovanni, V., Parruti, G., Sarmati, L., Coppola, N., Baldanti, F., Marco, V. Di, Zazzi, M., Raimondo, G., Angelico, M., Perno, C.F., Andreoni, M., Craxì, A., and Ceccherini-Silberstein, F.

Published
2020
Full Text
View/download PDF

23. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Allice, T., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Francioso, S., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Scuteri, A., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Gennari, W., Boeri, E., Morsica, G., Hasson, H., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Biliotti, E., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Merli, M., Rizzardini, G., Pellicelli, A., Giannelli, V., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Sighinolfi, L., Dentone, C., Lleo, A., Rossetti, B., Beretta, I., Cariti, G., Ghisetti, V., Lampertico, P., Parruti, G., Coppola, N., Baldanti, F., Gaeta, G.B., Raimondo, G., Puoti, M., Zazzi, M., Andreoni, M., Angelico, M., Perno, C.F., Craxì, A., and Ceccherini-Silberstein, F.

Published
2020
Full Text
View/download PDF

24. THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance

Author

Barbaliscia, Silvia, Maio, Velia Chiara Di, Teti, Elisabetta, Aragri, Marianna, Paolucci, Stefania, Masetti, Chiara, D’ambrosio, Roberta, Polilli, Ennio, Palitti, Valeria Pace, Fiorentino, Gianluca, Cento, Valeria, Scutari, Rossana, Bruzzone, Bianca, Calvaruso, Vincenza, Nicola, Coppola, Gaeta, Giovanni Battista, Morsica, Giulia, Ghisetti, Valeria, Bertoli, Ada, Milana, Martina, Foroghi, Luca, Nicolini, Laura Ambra, Borghi, Vanni, Campoli, Riccardo, Galli, Silvia, Magni, Carlo Federico, Micheli, Valeria, Boccaccio, Vincenzo, Maserati, Renato, Bonora, Stefano, Iapadre, Nerio, Morisco, Filomena, Siciliano, Massimo, Andreone, Pietro, Lichtner, Miriam, Paba, Pierpaolo, Sarmati, Loredana, Puoti, Massimo, Craxi, Antonio, Pellicelli, Adriano, Babudieri, Sergio, Rizzardini, Giuliano, Taliani, Gloria, Lampertico, Pietro, Pasquazzi, Caterina, Parruti, Giustino, Mario, Angelico, Andreoni, Massimo, Perno, Carlo Federico, and Silberstein, Francesca Ceccherini

Published
2019
Full Text
View/download PDF

25. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

Author

Maio, Velia Chiara Di, Aragri, Marianna, Masetti, Chiara, Paolucci, Stefania, Bruzzone, Bianca, Degasperi, Elisabetta, Barbaliscia, Silvia, Pollicino, Teresa, Minichini, Carmine, Calvaruso, Vincenza, Rendina, Maria Grazia, Cento, Valeria, Teti, Elisabetta, Micheli, Valeria, Ghisetti, Valeria, Polilli, Ennio, Palitti, Valeria Pace, Landonio, Simona, Lenci, Ilaria, Donnarumma, Laura, Nicolini, Laura Ambra, Bertoli, Ada, Pasquazzi, Caterina, Callegaro, Maria Paola, Morisco, Filomena, Cenderrello, Giovanni, Marenco, Simona, Gulminetti, Roberto, Novati, Stefano, Andreone, Pietro, Ciancio, Alessia, Sangiovanni, Vincenzo, Cuomo, Nunzia, Morsica, Giulia, Borghi, Vanni, Maida, Ivana Rita, Brunetto, Maurizia, Cozzolongo, Raffaele, Santis, Adriano De, Lichtner, Miriam, Babudieri, Sergio, Taliani, Gloria, Santantonio, Teresa, Paternoster, Claudio, Ganga, Roberto, Puoti, Massimo, Rizzardini, Giuliano, Pellicelli, Adriano, Lampertico, Pietro, Parruti, Giustino, Nicola, Coppola, Zazzi, Maurizio, Raimondo, Giovanni, Andreoni, Massimo, Craxi, Antonio, Mario, Angelico, Perno, Carlo Federico, and Ceccherini, Silberstein Francesca

Published
2019
Full Text
View/download PDF

26. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

Author

Barbaliscia, S., Di Maio, V.C., Teti, E., Aragri, M., Paolucci, S., Masetti, C., D’Ambrosio, R., Degasperi, E., Polilli, E., Palitti, V. Pace, Fiorentino, G., Foroghi, L., Cento, V., Scutari, R., Bruzzone, B., Calvaruso, V., Coppola, N., Gaeta, G.B., Morsica, G., Ghisetti, V., Bertoli, A., Milana, M., Nicolini, L.A., Gennari, W., Campoli, R., Galli, S., Magni, C.F., Micheli, V., Boccaccio, V., Maserati, R., Bonora, S., Iapadre, N., Morisco, F., Siciliano, M., Guarneri, V., Lichtner, M., Borghi, V., Paba, P., Sarmati, L., Puoti, M., Pellicelli, A., Babudieri, S., Rizzardini, G., Taliani, G., Parruti, G., Lampertico, P., Pasquazzi, C., Angelico, M., Baldanti, F., Craxì, A., Andreoni, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2019
Full Text
View/download PDF

27. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2019
Full Text
View/download PDF

29. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

Author

Piermatteo, L., Battisti, A., Carioti, L., Anastasiou, O., Gill, U.S., Colagrossi, L., Bertoli, A., Aragri, M., Iuvara, A., Malagnino, V., Cerva, C., Lichtner, M., Mastroianni, C.M., De Sanctis, G.M., Maurizio, P., Marignani, M., Pasquazzi, C., Iapadre, N., Mari, T., Parruti, G., Vecchiet, J., Sarmati, L., Andreoni, M., Mario, A., Grelli, S., Kennedy, P., Verheyen, J., Silberstein, F. Ceccherini, Perno, C.F., Salpini, R., and Svicher, V.

Published
2019
Full Text
View/download PDF

30. SAT-350 - A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Fabeni, L., Bertoli, A., Mastroianni, C.M., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Nicola, C., Marrone, A., Iapadre, N., Mario, A., Sarmati, L., Andreoni, M., Verheyen, J., Silberstein, F.C., Levrero, M., Perno, C.F., Belloni, L., and Svicher, V.

Published
2018
Full Text
View/download PDF

31. FRI-293 - Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Author

Salpini, R., Battisti, A., Carioti, L., Carlo, D.D., Anastasiou, O., Gill, U.S., Colagrossi, L., Bertoli, A., Aragri, M., Fabeni, L., Fini, V., Piermatteo, L., Iuvara, A., Malagnino, V., Cerva, C., Lichtner, M., Mastroianni, C.M., Sanctis, G.M.D., Maurizio, P., Marignani, M., Pasquazzi, C., Iapadre, N., Mari, T., Parruti, G., Vecchiet, J., Sarmati, L., Andreoni, M., Angelico, M., Grelli, S., Kennedy, P., Verheyen, J., Silberstein, F.C., Perno, C.F., and Svicher, V.

Published
2018
Full Text
View/download PDF

33. THU-359 - National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

Author

Ruggiero, T., Cento, V., Aragri, M., Arosio, M., Baldanti, F., Brunetto, M., Bruzzone, B., Boeri, E., Cavallone, D., Nicola, C., Stefano, M.A.D., Ghisetti, V., Callegaro, M.P., Capobianchi, M.R., Caudai, C., Cuomo, N., Galli, S., Galmozzi, E., Garbuglia, A., Gennari, W., Lai, A., Menzo, S., Micheli, V., Minosse, C., Monno, L., Paolucci, S., Pollicino, T., Raddi, A., Raffa, G., Raimondo, G., Sanguinetti, M., Santangelo, R., Santantonio, T., Soldini, S., Starace, M., Vatteroni, M.L., Craxi, A., Perno, C.F., Silberstein, F.C., and Zazzi, M.

Published
2018
Full Text
View/download PDF

34. THU-297 - Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Maio, V.C.D., Barbaliscia, S., Teti, E., Lenci, I., Aragri, M., Polilli, E., Fiorentino, G., Palitti, V.P., Bruzzone, B., Paolucci, S., Nicola, C., Ruggiero, T., Pollicino, T., Niero, F., Micheli, V., Nicolini, L.A., Marenco, S., Bertoli, A., Maida, I.R., Francioso, S., Foroghi, L., Calvaruso, V., Morisco, F., Lleo, A., Boccaccio, V., Ciancio, A., Maserati, R., Puoti, M., Zazzi, M., Rossetti, B., Vullo, V., D'ambrosio, R., Boglione, L., Bonora, S., Babudieri, S., Gubertini, G.A., Rendina, M.G., Pellicelli, A., Sangiovanni, V., Ciaccio, A., Taliani, G., Raimondo, G., Gaeta, G.B., Craxi, A., Pasquazzi, C., Sarmati, L., Parruti, G., Angelico, M., Andreoni, M., Cento, V., Perno, C.F., and Silberstein, F.C.

Published
2018
Full Text
View/download PDF

35. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

Author

Ruggiero, T., Cento, V., Aragri, M., Arosio, M., Baldanti, F., Brunetto, M., Bruzzone, B., Boeri, E., Cavallone, D., Coppola, N., Di Stefano, M., Ghisetti, V., Callegaro, A.P., Capobianchi, M.R., Caudai, C., Cuomo, N., Galli, S., Galmozzi, E., Garbuglia, A.R., Gennari, W., Lai, A., Menzo, S., Micheli, V., Minosse, C., Monno, L., Paolucci, S., Pollicino, T., Raddi, A., Raffa, G., Raimondo, G., Sanguinetti, M., Sampaolo, M., Santangelo, R., Santantonio, T., Soldini, S., Starace, M., Vatteroni, M.L., Craxì, A., Perno, C.F., Ceccherini-Silberstein, F., and Zazzi, M.

Published
2018
Full Text
View/download PDF

36. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Author

Barbaliscia, S., Di Maio, V.C., Teti, E., Lenci, I., Aragri, M., Polilli, E., Fiorentino, G., Pace Palitti, V., Bruzzone, B., Paolucci, S., Coppola, N., Ruggiero, T., Pollicino, T., Niero, F., Micheli, V., Nicolini, L.A., Marenco, S., Bertoli, A., Maida, I., Francioso, S., Foroghi, L., Calvaruso, V., Morisco, F., Lleo, A., Boccaccio, V., Ciancio, A., Maserati, R., Puoti, M., Zazzi, M., Rossetti, B., Vullo, V., D’Ambrosio, A.R., Boglione, L., Bonora, S., Babudieri, S., Gubertini, G., Rendina, M., Pellicelli, A., Sangiovanni, V., Ciaccio, A., Taliani, G., Raimondo, G., Gaeta, G.B., Craxì, A., Pasquazzi, C., Sarmati, L., Parruti, G., Angelico, M., Andreoni, M., Cento, V., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2018
Full Text
View/download PDF

37. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.

Author

Cento, Valeria, Aragri, Marianna, Teti, Elisabetta, Polilli, Ennio, Bertoli, Ada, Foroghi, Luca, Barbaliscia, Silvia, Di Maio, Velia Chiara, Pieri, Alessandro, Palitti, Valeria Pace, Sarmati, Loredana, Parruti, Giustino, Andreoni, Massimo, Perno, Carlo Federico, Ceccherini-Silberstein, Francesca, and Pace Palitti, Valeria

Subjects
*HEPATITIS C virus, *ANTIVIRAL agents, *CIRRHOSIS of the liver, *RNA virus infections, *ORAL drug administration, *PATIENTS
Abstract

Background: Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%.Objectives: As proof-of-concept, we evaluated the efficacy of all-oral direct-acting antiviral (DAA) regimens in patients whose personalization included pre-therapy evaluation of natural resistance-associated substitutions (RASs), in addition to international guideline recommendations.Methods: One hundred and thirty-one patients who started a first-line all-oral DAA regimen between April 2015 and December 2016 were tested for baseline NS3 and NS5A RASs by Sanger sequencing. SVR12 was defined as HCV-RNA undetectability 12 weeks after treatment discontinuation.Results: Compatibly with a real-life context, 74.0% (97 of 131) of patients presented ≥2 pretreatment risk factors for failure to achieve SVR12 (infection by GT-1a/GT-3a; cirrhosis; previous treatment experience; HCV-RNA ≥800 000 IU/mL) and 33.6% had ≥3 risk factors. Natural RASs were frequently detected (32.1% prevalence), with substantial prevalence of NS5A RASs (15.3%), mostly represented by Y93H in GT-1b (3 of 36, 8.3%) and GT-3a (3 of 25, 12.0%) and F28C in GT-2c (2 of 11, 18.2%). Overall, personalized treatment led to 100% SVR12, even in those patients for whom treatment strategy was either strengthened (by ribavirin inclusion and/or duration increase) or simplified (by ribavirin exclusion and/or duration reduction), thanks to baseline RAS evaluation.Conclusions: Even with newer DAA regimens, an integrated interpretation of clinical and virological pretreatment parameters, including natural RASs, may play a relevant role in bringing SVR rates close to the highest achievable. Treatment tailoring can be foreseen in 'hard-to-treat' patients, but also in 'easy' patients with favourable indicators, whereby a simplification/shortening of recommended regimens can be indicated. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

38. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

Author

Micheli, V., Troshina, Y., Biliotti, E., Milana, M., Melis, M., Teti, E., Lambiase, L., Menzaghi, B., Nicolini, L.A., Marenco, S., Di Maio, V.C., Aragri, M., Pecchioli, A., Bertoli, A., Sarrecchia, C., Macera, M., Coppola, N., Puoti, M., Romagnoli, D., Pellicelli, A., Bonora, S., Novati, S., Baldanti, F., Ghisetti, V., Andreoni, M., Taliani, G., Rizzardini, G., Angelico, M., Cento, V., Barbaliscia, S., Lenci, I., Ruggiero, T., Magni, C.F., Paolucci, S., Babudieri, S., Siciliano, M., Pasquazzi, C., Ciancio, A., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

39. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

Author

Di Maio, V.C., Barbaliscia, S., Lenci, I., Teti, E., Antonucci, F.P., Cento, V., Aragri, M., Paolucci, S., Bruzzone, B., Coppola, N., Ruggiero, T., Pollicino, T., Polilli, E., Pasquazzi, C., Pace Palitti, V., Magni, C.F., Micheli, V., Di Biagio, A., Sticchi, L., Melis, M., Francioso, S., Masetti, C., Foroghi, L., Sarrecchia, C., Baiocchi, L., Landonio, S., Bertoli, A., Calvaruso, V., Morisco, F., Maida, I., Marenco, S., Leo, A., Ghisetti, V., Ciancio, A., Sacchi, P., Novati, S., Brancaccio, G., Pieri, A., Puoti, M., Toniutto, P., Vullo, V., Aghemo, A., Di Perri, G., Babudieri, S., Rizzardini, G., Bruno, S., Pellicelli, A., Taliani, G., Raimondo, G., Baldanti, F., Gaeta, G.B., Craxì, A., Parruti, G., Andreoni, M., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

40. Natural HCV resistance is common in Italy and differently associated to genotypes

Author

Sorbo, M.C., Cento, V., Bertoli, A., Lenci, I., Polilli, E., Masetti, C., Gianserra, L., Teti, E., Biliotti, E., Magni, C.F., Aragri, M., Micheli, V., Melis, M., Nicolini, L.A., Marenco, S., Calvaruso, V., Paolucci, S., Baldanti, F., Morisco, F., Siciliano, M., Pace Palitti, V., Andreone, P., Bruzzone, B., Coppola, N., Ruggiero, T., Lichtner, M., Menzaghi, B., Romagnoli, D., Iapadre, N., Di Maio, V.C., De Leonardis, F., Milana, M., Cacciatore, P., Pieri, A., Sarmati, L., Landonio, S., Gasbarrini, A., Puoti, M., Craxì, A., Vullo, V., Pellicelli, A., Babudieri, S., Rizzardini, G., Taliani, G., Andreoni, M., Pasquazzi, C., Parruti, G., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

41. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Di Maio, V.C., Cento, V., Lenci, I., Aragri, M., Barbaliscia, S., Francioso, S., Paolucci, S., Melis, M., Verucchi, G., Masetti, C., Coppola, N., Magni, C.F., Micheli, V., Pollicino, T., Ruggiero, T., Landonio, S., Mancon, A., Starace, M., De Leonardis, F., Santopaolo, F., Bertoli, A., Antonucci, F.P., D’Ambrosio, C., Calvaruso, V., Sorbo, M.C., Morisco, F., Pasquazzi, C., Maida, I., Picciotto, A., Di Biagio, A., Bruzzone, B., Sticchi, L., Ghisetti, V., Cozzolongo, R., Romagnoli, D., Boccaccio, V., Grieco, A., Vecchiet, J., D’Ettorre, G., Merli, M., Gaeta, G.B., Ciancio, A., Marinaro, L., Polilli, E., Cacciatore, P., Andreone, P., Barbarini, G., Gulminetti, R., Novati, S., Pace Palitti, V., Tarquini, P., Puoti, M., Sangiovanni, V., De Stefano, G., Giorgini, A., Paoloni, M., Caporaso, N., Babudieri, S., Gubertini, G., Bruno, S., Andreoni, M., Pellicelli, A., Parruti, G., Raimondo, G., Baldanti, F., Rizzardini, G., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

42. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

Author

Cento, V., Barbaliscia, S., Lenci, I., Ruggiero, T., Masetti, C., Magni, C.F., Micheli, V., Paolucci, S., Troshina, Y., Biliotti, E., Milana, M., Melis, M., Teti, E., Lambiase, L., Menzaghi, B., Nicolini, L.A., Marenco, S., Di Maio, V.C., Aragri, M., Pecchioli, A., Bertoli, A., Antonucci, F.P., Sarmati, L., Sarrecchia, C., Macera, M., Coppola, N., Danieli, E., Romagnoli, D., Pellicelli, A., Bonora, S., Babudieri, S., Di Biagio, A., Picciotto, A., Novati, S., Siciliano, M., Messina, V., Claar, E., Baldanti, F., Pasquazzi, C., Ciancio, A., Puoti, M., Ghisetti, V., Andreoni, M., Taliani, G., Rizzardini, G., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

43. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

Author

Cento, V., Barbaliscia, S., Di Maio, V.C., Masetti, C., Minichini, C., Magni, C.F., Micheli, V., Marenco, S., Nicolini, L.A., Bruzzone, B., Troshina, Y., Baiguera, C., Dentone, C., Calvaruso, V., Paolucci, S., Melis, M., Aragri, M., Bertoli, A., Lenci, I., Landonio, S., Schiavini, M., Sticchi, L., Ruggiero, T., Polilli, E., Messina, V., Pellicelli, A., Boglione, L., Cozzolongo, R., Biolato, M., Morisco, F., Siciliano, M., Parruti, G., Barbarini, G., Craxì, A., Babudieri, S., Puoti, M., Ciancio, A., Rizzardini, G., Coppola, N., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

44. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

Author

Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, FrancescoPaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., and Calvaruso, Vincenza

Subjects
HEPATITIS C treatment, ANTIVIRAL agents, DRUG resistance in microorganisms, SOFOSBUVIR, GENOTYPES, INTERFERONS
Abstract

Background & Aims Despite the excellent efficacy of direct-acting antivirals ( DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions ( RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (Peg IFN+ RBV) and 111 without ( HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/ NS5A/ NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70). Results The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/ RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A- RASs (96.1%), compared to NS3- RASs (75.9% with IFN, 70.5% without) and NS5B- RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major- RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+ NS5A failures. Furthermore, 20.0% of patients had baseline- RASs, which were always confirmed at failure. Conclusions In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

45. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.

Author

Cuypers, Lize, Vrancken, Bram, Fabeni, Lavinia, Marascio, Nadia, Cento, Valeria, Di Maio, Velia Chiara, Aragri, Marianna, Pineda-Peña, Andrea Clemencia, Schrooten, Yoeri, Van Laethem, Kristel, Balog, Daniel, Focà, Alfredo, Torti, Carlo, Nevens, Frederik, Perno, Carlo Federico, Vandamme, Anne-Mieke, and Ceccherini-Silberstein, Francesca

Subjects
HEPATITIS C virus, VIRAL genetics, PHYLOGEOGRAPHY, HEALTH policy, PUBLIC health, HEPATITIS C, PATIENTS
Abstract

Background: In-depth phylogeographic analysis can reveal migration patterns relevant for public health planning. Here, as a model, we focused on the provenance, in the current Italian HCV subtype 1a epidemic, of the NS3 resistance-associated variant (RAV) Q80K, known to interfere with the action of NS3/4A protease inhibitor simeprevir. HCV1a migration patterns were analysed using Bayesian phylodynamic tools, capitalising on newly generated and publicly available time and geo-referenced NS3 encoding virus genetic sequence data. Results: Our results showed that both immigration and local circulation fuel the current Italian HCV1a epidemic. The United States and European continental lineages dominate import into Italy, with the latter taking the lead from the 1970s onwards. Since similar migration patterns were found for Q80K and other lineages, no clear differentiation of the risk for failing simeprevir can be made between patients based on their migration and travel history. Importantly, since HCV only occasionally recombines, these results are readily transferable to the genetic sequencing policy concerning NS5A RAVs. Conclusions: The patient migration and travel history cannot be used to target only part of the HCV1a infected population for drug resistance testing before start of antiviral therapy. Consequently, it may be cost-effective to expand genotyping efforts to all HCV1a infected patients eligible for simeprevir-based therapies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

Author

Di Maio, V.C., Cento, V., Di Paolo, D., Lenci, I., Aragri, M., Verucchi, G., Melis, M., Bertoli, A., Antonucci, F.P., Francioso, S., Pellicelli, A., Calvaruso, V., Pasquazzi, C., Romagnoli, D., Rosa, K. Yu La, Campoli, R., Biolato, M., Vecchiet, J., Sorbo, M.C., Morisco, F., Merli, M., Brancaccio, G., Gaeta, G.B., Brillanti, S., Donato, F., Puoti, M., Pisani, V., Grieco, A., Caporaso, N., Paoloni, M., Babudieri, S., Mura, M.S., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2016
Full Text
View/download PDF

47. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

Author

Aragri, M., Di Maio, V.C., Di Paolo, D., Cento, V., De Leonardis, F., Gianserra, L., Tontodonati, M., Micheli, V., Landonio, S., Manunta, A., Bertoli, A., Ciotti, M., Antonucci, F.P., Campoli, R., La Rosa, K. Yu, Deodati, F., Lenci, I., Francioso, S., Nicolini, L.A., Marenco, S., Teti, E., Lambiase, L., Milana, M., Maida, I., Di Biagio, A., Pellicelli, A., Nosotti, L., Grieco, S., Cacciatore, P., Romagnoli, D., Siciliano, M., D’Ettorre, G., Babudieri, S., Lichtner, M., Vespasiani-Gentilucci, U., Romano, M., Sarrecchia, C., Grieco, A., Morisco, F., Mastroianni, C., Vecchiet, J., Puoti, M., D’Amico, E., Caporaso, N., Gasbarrini, A., Bruno, S., Magni, C., Mura, M.S., Taliani, G., Picciotto, A., Rizzardini, G., Andreoni, M., Pasquazzi, C., Parruti, G., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2016
Full Text
View/download PDF

48. THU-263 - In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment

Author

Aragri, M., Di Maio, V.C., Di Paolo, D., Cento, V., De Leonardis, F., Gianserra, L., Tontodonati, M., Micheli, V., Landonio, S., Manunta, A., Bertoli, A., Ciotti, M., Antonucci, F.P., Lenci, I., Francioso, S., Nicolini, L.A., Marenco, S., Teti, E., Lambiase, L., Milana, M., Maida, I., Di Biagio, A., Pellicelli, A., Nosotti, L., Grieco, S., Cacciatore, P., Romagnoli, D., Siciliano, M., D’Ettorre, G., Babudieri, S., Lichtner, M., Gentilucci, U.V., Romano, M., Sarrecchia, C., Grieco, A., Morisco, F., Mastroianni, C., Vecchiet, J., Puoti, M., D’Amico, E., Gasbarrini, A., Bruno, S., Magni, C., Mura, M.S., Taliani, G., Picciotto, A., Rizzardini, G., Andreoni, M., Pasquazzi, C., Parruti, G., Angelico, M., Perno, C.F., and Silberstein, F.C.

Published
2016
Full Text
View/download PDF

49. THU-241 - Virological Failures to New Direct Acting Antivirals in a Real Life Setting May Require Unconventional Regimens for Re-Treatment

Author

Di Maio, V.C., Cento, V., Di Paolo, D., Lenci, I., Aragri, M., Verucchi, G., Melis, M., Bertoli, A., Antonucci, F.P., Francioso, S., Pellicelli, A., Calvaruso, V., Pasquazzi, C., Romagnoli, D., Biolato, M., Vecchiet, J., Morisco, F., Merli, M., Gaeta, G.B., Brillanti, S., Donato, F., Puoti, M., Pisani, V., Paoloni, M., Babudieri, S., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results